Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furazolidone vs Clarithromycin Quadruple Therapy for First-line H. Pylori Eradication
NCT06823791Phase 2Completed
- Sponsor
- Liaocheng City People's Hospital
- Start
- Aug 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of furazolidone in Helicobacter pylori infection (2 arms), sponsored by Liaocheng City People's Hospital. Primary endpoint: Helicobacter Pylori Eradication Rate at 6 months. Started Aug 2022; status: completed.
02
Drugs
furazolidone
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06823791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06823791.